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EDITORIAL COMMENT
The Prudent Person’s Paradox*
Fredric J. Pashkow, MD, FACC
Honolulu, Hawaii
We can all name a number of people—friends, family, and
patients among them—who, despite conscientious effort on
their part and the achievement of what for all intents and
purposes appears to be a “normal” risk factor profile,
experience an acute coronary event. The “Prudent Person’s
Paradox,” if you will, is a sort of antithesis of the “French
Paradox,” where, despite what appears to be a predisposing
diet and lifestyle, the French maintain(ed) a lower than
expected incidence of coronary heart disease (CHD) (1).
See page 1475
In this issue of the Journal, the paper by Akosah et al. (2)
regarding the ability of the new National Cholesterol
Education Program guidelines (3) to identify people need-
ing aggressive coronary risk factor intervention, provides
elaborate documentation of this phenomenon. The authors
found that even though the new guidelines essentially “widen
the net” for those who should receive greater attention to risks,
they still underestimate the risk of acute coronary events in
“young adults” (men 55 years of age and women 65 years
of age). For example, as many as 58% had low-density
lipoprotein cholesterol levels 130 mg/dl and 50% did not
have multiple risk factors. Only 25% of the men and 18% of
the women were appropriately identified for lipid-lowering
pharmacotherapy. Similarly, among the subjects with moder-
ate risk (10% to 20%), only half were treatment-eligible. Of the
subjects, 70% actually fell into the lowest two risk categories.
More people qualified for pharmacologic intervention in the
lowest risk category (8% of subjects) than in the third quartile
(1% of subjects with 2 risk factors,10% risk). Why, despite
all the time and earnest effort expended for their revision, do
such guidelines still seem so off the mark? Earnest practitioners
want to know: does risk factor scoring translate into clinically
relevant decision making?
Problems with accuracy of risk estimation. Biologic vari-
ation in risk factors affects the accuracy of correct categori-
zation of patients in primary prevention screening. Reynolds
et al. (4) showed that at internationally recommended
10-year CHD risk treatment threshold levels of 15%, 20%,
and 30%, the 95% confidence intervals were: 5.1%,
6.0%, and 6.9% for single-point; 3.6%, 4.2%, and
4.9% for duplicate-point; and2.8%,3.3%, and3.9%
for triplicate estimates, respectively. Consequently, using
the 30% risk threshold with single-point estimation, 30% of
patients who should receive treatment would be denied it
and 20% would receive treatment unnecessarily, figures very
consistent with the observations of Akosah et al. (2).
“Multiple measurements improve precision but cannot ab-
solutely define risk,” conclude Reynolds et al. (4). This study
suggests that biologic variation in cardiovascular risk factors
has profound consequences on calculated risk for therapeu-
tic decision making and probably contributes to the inac-
curacy of risk estimation.
Imprecise measurement of risk factors causes misclassifi-
cation of individuals, limits sensitivity to detect those with
true high risk, and dilutes associations between risk factors
and disease (5). For cholesterol and CHD (a linear relation-
ship), uncorrected estimates tended to exaggerate the effec-
tiveness of “high-risk” strategies relative to the “population-
based” approach.
Haq et al. (6) found that methods based on cholesterol
threshold and counting of risk factors to be too inaccurate
for targeting drug therapy for primary prevention of CHD.
They compared the accuracy of several CHD risk assess-
ment methods and found that cholesterol threshold (6.5
mmol/l) plus two risk factors had a sensitivity of 59% and
specificity of 63% and, thus, misidentified some very high-
and low-risk patients. Framingham-based methods using
total cholesterol alone had a sensitivity of 90% to 98% and
specificity 37% to 43%, identifying high-risk patients well,
but inappropriately identifying some at very low risk.
Methods based on total cholesterol:high-density lipoprotein
cholesterol ratio had a sensitivity of 90% to 98% and
specificity 60% to 63%, and did not incorrectly identify
people at very low CHD risk.
The right questions . . . the right answers. There’s an old
adage that you will not get the right answers if you are
asking the wrong questions. Frankly, it seems practitioners
tend to apply diagnostic tests for coronary disease in their
historical context, rather than how they fit currently into the
most up-to-date understanding of the coronary disease
continuum. What is it that you want to know? Is it if
someone has a disease that is advanced to the point where
revascularization should be considered? Or, are they at
near-term risk of plaque rupture? For the appropriate
initiation of medical therapy, we need to know if there is any
disease present, not 50% obstruction, an arbitrary definition
of CHD, or even 65% obstruction when compromised
perfusion during stress can be documented. By the time
people experience their first coronary event, the disease is, in
fact, fairly advanced and the likelihood of something unto-
ward occurring is great (7). We should be thinking more of
identifying who is the vulnerable patient rather than who
has the vulnerable plaque (8).
If you want to answer the question of whether someone
has any evidence of the disease, then subclinical diagnostic
modalities are required. Such surrogate markers are now
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available and are being further investigated to identify
disease in its early phases in an attempt to decrease cardio-
vascular morbidity and mortality. Coronary artery calcifica-
tion is a useful surrogate marker of coronary artery disease,
and it can be visualized and measured noninvasively by
means of electron beam tomography (EBT) imaging (9).
This is an especially challenging issue for the early identi-
fication of at-risk women. Assuming a higher risk in
subjects with EBT-defined subclinical CHD than in those
without, only 58.6% of a female cohort of subjects would be
correctly identified by NCEP guidelines as either higher or
lower risk, with correct identification of 65.5% of the
younger and 52.2% of the older women (10). Such studies
demonstrate the shortcomings of employing guidelines to
identify asymptomatic women with subclinical CHD, par-
ticularly women older than 55 years, and suggest the need
for validation and increased application of subclinical mark-
ers for primary prevention in the female population. Risk
scoring systems will always perform best for assessing
populations, but will predictably fall short if relied on for
individual patient management decisions.
If you want to know who may be a candidate for an
impending acute coronary event, then clearly the application
of newer risk markers such as high sensitivity C-reactive
protein will be the tools of choice (11), in addition to
playing an important role as an adjunct for global risk
assessment in the primary prevention of cardiovascular
disease (12), and for identifying individuals with normal
lipid levels who are at increased risk for future coronary
events (13). In time, other emerging technologies will likely
be available (14,15).
Precluding the prudent person’s paradox. As advocates
for the public and our patients, we need to apply both a
population strategy and a clinical strategy (16). Determina-
tion of risk scores will help us identify the vulnerable patient
who needs aggressive management of modifiable risks, even
if it does not necessarily identify the patient’s precise
location on the coronary continuum (17). This applies
equally to those who are thought to be low- to moderate-
risk based upon lipid profile or multifactorial risk assessment
(18,19). In addition, the careful application of novel com-
plementary diagnostic technologies will provide relief to
those who are candidates for the inevitable disappointment
of the prudent person’s paradox.
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